Unsuspected and paradoxical potential for drug interaction by rifampin: Things to ponder with antiretroviral therapy

Journal of Infectious Diseases

Volumn 199, Issue 5, 2009, Pages 766-767

  Srinivas, Nuggehally R ^a  

^a Suramus Biopharm   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BOSENTAN; CYTOCHROME P450 ISOENZYME; DIGOXIN; EZETIMIBE; NELFINAVIR; RIFAMPICIN; SILDENAFIL;

BILIARY EXCRETION; DEVELOPING COUNTRY; HUMAN; LETTER; NONHUMAN; PARADOXICAL DRUG REACTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; RIFAMPIN;

EID: 61849085734     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596746     Document Type: Letter

References (10)

1. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis 2008; 198:948-61.
2. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004; 277:3-9.
3. Dixit V, Hariprasad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by antihuman immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35:1853-9.
4. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81:194-204.
5. Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35:1400-7.
6. Weiss M, Hung DY, Poenicke K, Roberts MS. Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin. Eur J Pharm Sci 2008; 34:345-50.
7. Burgess G, Hoogkamer H, Collings L, Dingermanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64:43-50.
8. Oswald S, Giessmann T, Luetjohann D. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 2006; 80:477-85.
9. Naesens M, Kuypers DR, Streit F, et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006; 80:509-21.
10. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 2004; 32:1462-7.